Savara Inc.
SVRA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 14.3%, free cash flow fell 14.1% and total debt rose 1.54%, each against the same quarter a year earlier.
Follow SVRA
Savara Inc. (SVRA) Altman Z-score
Savara Inc.'s Altman Z-score for fiscal 2020 is −3.18, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2020 | −3.18 | — |
How fiscal 2020’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.79 | — | 0.94 | |
| Retained earnings / total assets | (2.63) | — | −3.69 | |
| EBIT / total assets | (0.50) | — | −1.66 | |
| Market value of equity / total liabilities | 2.04 | — | 1.23 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −3.18 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −4.79 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CGEM Cullinan Therapeutics, Inc. compare | 33.6× |
| JANX Janux Therapeutics, Inc. compare | 11.6× |
| IMTX Immatics N.V. compare | 6.8× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.7× |
| SVRA Savara Inc. | −3.2× |
| MNKD MannKind Corporation compare | −3.6× |
| MGTX MeiraGTx Holdings PLC compare | −4.4× |
| ANRO Alto Neuroscience, Inc. compare | — |
| AKTS Aktis Oncology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets